Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2018

01-10-2018 | Translational Research and Biomarkers

Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers

Authors: Amanda N. Graff-Baker, MD, Javier I. J. Orozco, MD, Diego M. Marzese, PhD, Matthew P. Salomon, PhD, Dave S. B. Hoon, PhD, Melanie Goldfarb, MD, MSc, FACS, FACE

Published in: Annals of Surgical Oncology | Issue 10/2018

Login to get access

Abstract

Background

Molecular alterations impact tumor prognosis and response to treatment. This study was designed to identify transcriptomic and epigenomic signatures of breast cancer (BC) tumors from patients with any prior malignancy.

Methods

RNA-sequencing and genome-wide DNA methylation profiles from BCs were generated in the Cancer Genome Atlas project. Patients with secondary breast cancer (SBC) were separated by histological subtype and matched to primary breast cancer controls to create two independent cohorts of invasive ductal (IDC, n = 36) and invasive lobular (ILC, n = 40) carcinoma. Differentially expressed genes, as well as differentially methylated genomic regions, were integrated to identify epigenetically regulated abnormal gene pathways in SBCs.

Results

Differentially expressed genes were identified in IDC SBCs (n = 727) and in ILC SBCs (n = 261; Wilcoxon’s test; P < 0.05). In IDC SBCs, 105 genes were upregulated and hypomethylated, including an estrogen receptor gene, and 73 genes were downregulated and hypermethylated, including genes involved in antigen presentation and interferon response pathways (HLA-E, IRF8, and RELA). In ILC SBCs, however, only 17 genes were synchronously hypomethylated and upregulated, whereas 46 genes hypermethylated and downregulated. Interestingly, the SBC gene expression signatures closely corresponded with each histological subtype with only 1.51% of genes overlapping between the two histological subtypes.

Conclusions

Differential gene expression and DNA methylation signatures are seen in both IDC and ILC SBCs, including genes that are relevant to tumor growth and proliferation. Differences in gene expression signatures corresponding with each histological subtype emphasize the importance of disease subtype-specific evaluations of molecular alterations.
Literature
1.
go back to reference Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed
2.
go back to reference Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRefPubMed Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRefPubMed
3.
go back to reference Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRefPubMedPubMedCentral Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRefPubMedPubMedCentral
4.
go back to reference Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRefPubMed Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRefPubMed
5.
go back to reference Behrens C, Travis LB, Wistuba, II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1027–35.PubMed Behrens C, Travis LB, Wistuba, II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1027–35.PubMed
6.
go back to reference Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin’s lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28(34):5088–96.CrossRefPubMedPubMedCentral Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin’s lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28(34):5088–96.CrossRefPubMedPubMedCentral
7.
go back to reference Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29(18):2466–73.CrossRefPubMedPubMedCentral Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29(18):2466–73.CrossRefPubMedPubMedCentral
8.
go back to reference Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. bioRxiv. 2018. Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. bioRxiv. 2018.
9.
go back to reference Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems. 2016;12(2):477–9.CrossRefPubMed Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems. 2016;12(2):477–9.CrossRefPubMed
11.
12.
go back to reference Gomez LC, Sottile ML, Guerrero-Gimenez ME, et al. TP73 DNA methylation and upregulation of DeltaNp73 are associated with an adverse prognosis in breast cancer. J Clin Pathol. 2018;71(1):52–8.CrossRefPubMed Gomez LC, Sottile ML, Guerrero-Gimenez ME, et al. TP73 DNA methylation and upregulation of DeltaNp73 are associated with an adverse prognosis in breast cancer. J Clin Pathol. 2018;71(1):52–8.CrossRefPubMed
13.
go back to reference Marzese DM, Gago FE, Orozco JI, Tello OM, Roque M, Vargas-Roig LM. Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. J Med Case Rep. 2011;5:516.CrossRefPubMedPubMedCentral Marzese DM, Gago FE, Orozco JI, Tello OM, Roque M, Vargas-Roig LM. Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. J Med Case Rep. 2011;5:516.CrossRefPubMedPubMedCentral
14.
go back to reference Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Molec Cell Probes. 2010;24(5):271–80.CrossRefPubMed Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Molec Cell Probes. 2010;24(5):271–80.CrossRefPubMed
15.
go back to reference Marzese DM, Hoon DS, Chong KK, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Molec Diagnos. 2012;14(6):613–22.CrossRef Marzese DM, Hoon DS, Chong KK, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Molec Diagnos. 2012;14(6):613–22.CrossRef
16.
go back to reference Urrutia G, Laurito S, Marzese DM, et al. Epigenetic variations in breast cancer progression to lymph node metastasis. Clin Exp Met. 2015;32(2):99–110.CrossRef Urrutia G, Laurito S, Marzese DM, et al. Epigenetic variations in breast cancer progression to lymph node metastasis. Clin Exp Met. 2015;32(2):99–110.CrossRef
17.
go back to reference Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
19.
go back to reference Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e699. Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e699.
20.
go back to reference Iida Y, Ciechanover A, Marzese DM, et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-kappaB Pathway in Melanoma. Clin Cancer Res. 2017;23(16):4831–42.CrossRefPubMedPubMedCentral Iida Y, Ciechanover A, Marzese DM, et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-kappaB Pathway in Melanoma. Clin Cancer Res. 2017;23(16):4831–42.CrossRefPubMedPubMedCentral
21.
go back to reference Bustos MA, Salomon MP, Nelson N, et al. Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Gen Data. 2017;12:14–6.CrossRef Bustos MA, Salomon MP, Nelson N, et al. Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Gen Data. 2017;12:14–6.CrossRef
22.
go back to reference Marzese DM, Witz IP, Kelly DF, Hoon DS. Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. Epigenomics. 2015;7(8):1303–11.CrossRefPubMed Marzese DM, Witz IP, Kelly DF, Hoon DS. Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. Epigenomics. 2015;7(8):1303–11.CrossRefPubMed
23.
go back to reference Marzese DM, Huynh JL, Kawas NP, Hoon DS. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Gen Data. 2014;2:150–2.CrossRef Marzese DM, Huynh JL, Kawas NP, Hoon DS. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Gen Data. 2014;2:150–2.CrossRef
24.
go back to reference Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol. 2015;10(3):509–17.CrossRefPubMed Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol. 2015;10(3):509–17.CrossRefPubMed
25.
go back to reference Wang J, Huang SK, Marzese DM, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Ddermatol. 2015;135(2):532–41.CrossRef Wang J, Huang SK, Marzese DM, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Ddermatol. 2015;135(2):532–41.CrossRef
26.
go back to reference Marzese DM, Liu M, Huynh JL, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.CrossRefPubMed Marzese DM, Liu M, Huynh JL, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.CrossRefPubMed
27.
go back to reference Marzese DM, Scolyer RA, Roque M, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-oncology. 2014;16(11):1499–1509.CrossRefPubMedPubMedCentral Marzese DM, Scolyer RA, Roque M, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-oncology. 2014;16(11):1499–1509.CrossRefPubMedPubMedCentral
28.
go back to reference Marzese DM, Scolyer RA, Huynh JL, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Mol Gen. 2014;23(1):226–38.CrossRef Marzese DM, Scolyer RA, Huynh JL, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Mol Gen. 2014;23(1):226–38.CrossRef
29.
30.
go back to reference Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Gen. 2016;17(5):284–99.CrossRef Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Gen. 2016;17(5):284–99.CrossRef
31.
go back to reference Winkelmann N, Schafer V, Rinke J, et al. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017;143(12):2511–9.CrossRefPubMed Winkelmann N, Schafer V, Rinke J, et al. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017;143(12):2511–9.CrossRefPubMed
32.
go back to reference Chen JY, Luo CW, Lai YS, Wu CC, Hung WC. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.CrossRefPubMedPubMedCentral Chen JY, Luo CW, Lai YS, Wu CC, Hung WC. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.CrossRefPubMedPubMedCentral
33.
go back to reference Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007;67(7):3301–9.CrossRefPubMed Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007;67(7):3301–9.CrossRefPubMed
Metadata
Title
Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers
Authors
Amanda N. Graff-Baker, MD
Javier I. J. Orozco, MD
Diego M. Marzese, PhD
Matthew P. Salomon, PhD
Dave S. B. Hoon, PhD
Melanie Goldfarb, MD, MSc, FACS, FACE
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 10/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6582-7

Other articles of this Issue 10/2018

Annals of Surgical Oncology 10/2018 Go to the issue